semaglutide news oct 26 2025 Are you eligible? Medicare's new GLP-1 Bridge program will cover certain weight-loss drugs starting this week. But as of now, the program isn't permanent: http://www.wkyc.com/article/news/nation-world/medicare-covering-glp-1-weight-loss-drugs-bridge FDA approves Novo Nordisk's new

Gallstones were more common with semaglutide (about 2.6% vs 1.2% with placebo) in the STEP trials, consistent with rapid weight loss in general

Please try again According to the Canadian Patent Database, Novo Nordisk was first issued the patent in 2013 but it is now expired and beyond the period of reversal. A report by Science said the pharma company last paid the annual maintenance fee on 2018, which at the time was $250

Of those patients on treatment at 1 year, 76% were on the 2.4 mg dose, 8% were on the 1.7 mg dose, and 16% were on lower doses

Our team submits clinical documentation, addresses insurer queries, and persistently follows up to secure a decision

Tracking waist measurements, lab results, energy levels, and menstrual cycle regularity can all tell you a lot about whether your program is working

The maker of Wegovy is threatening to sue and take regulatory action, saying Hims & Hers' new weight loss medication is illegal and calling it an "unapproved, inauthentic and untested knockoff semaglutide pill." "The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety